Gilead Sciences Inc

Latest stories

4d
Business Wire
Gilead Sciences to Participate in Two Upcoming Investor ConferencesFOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) toda
Gilead Sciences to Participate in Two Upcoming Investor Conferences
Business Wire / Posted 4 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced webcasts from two upcoming investor conferences: the 18th Annual BIO CEO & Investor Conference and the Leerink Partners 5th Annual Global Healthcare... Read more
6d
Business Wire
Gilead Sciences gibt Finanzergebnisse für viertes Quartal und Gesamtjahr 2015 bekanntFOSTER CITY, Kalifornien--(BUSINESS WIRE)--Das Unternehmen Gilead Sciences, Inc
Gilead Sciences gibt Finanzergebnisse für viertes Quartal und Gesamtjahr 2015 bekannt
Business Wire / Posted 6 days ago
FOSTER CITY, Kalifornien--(BUSINESS WIRE)--Das Unternehmen Gilead Sciences, Inc. (Nasdaq: GILD) hat heute seine Geschäftsergebnisse für das vierte Quartal und das Gesamtjahr 2015 bekannt gegeben. Der Gesamtumsatz im vierten Quartal 2015 belief sich... Read more
2966 related stories
7d
Business Wire
Gilead Sciences annonce ses résultats financiers pour le quatrième trimestre et l’exercice 2015FOSTER CITY, Californie--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq : GILD)
Gilead Sciences annonce ses résultats financiers pour le quatrième trimestre et l’exercice 2015
Business Wire / Posted 7 days ago
FOSTER CITY, Californie--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq : GILD) a annoncé aujourd’hui ses résultats d’exploitation pour le quatrième trimestre et l’exercice 2015. Le chiffre d’affaires total pour le quatrième trimestre 2015 a été de... Read more
502 related stories
7d
Business Wire
Gilead Sciences maakt financiële resultaten van het vierde kwartaal en van het gehele jaar 2015 bekendFOSTER CITY, Californië--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD)
Gilead Sciences maakt financiële resultaten van het vierde kwartaal en van het gehele jaar 2015 bekend
Business Wire / Posted 7 days ago
FOSTER CITY, Californië--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) heeft vandaag haar bedrijfsresultaten bekendgemaakt voor het vierde kwartaal en het gehele jaar 2015. De totale opbrengsten voor het vierde kwartaal van 2015 waren $ 8,5... Read more
26 related stories
9d
Morningstar
Merck Revenue and Profit FallsShares, which have fallen 6% in the last three months, fell 2.8% in premarket t
Merck Revenue and Profit Falls
Morningstar / Posted 9 days ago
Shares, which have fallen 6% in the last three months, fell 2.8% in premarket trading. Merck said it expects 2016 adjusted earnings per share of between $3.60 and $3.75 and revenue between $38.7 billion and $40.2 billion. Analysts polled by Thomson... Read more
7 related stories
9d
FOX Business
Merck Revenue and Profit FallsMerck posted declines in sales and profit as the pharmaceutical giant gave reve
Merck Revenue and Profit Falls
FOX Business / Posted 9 days ago
Merck posted declines in sales and profit as the pharmaceutical giant gave revenue projections below analyst forecasts and earnings expectations on the lower end of them. Shares, which have fallen 6% in the last three months, fell 2.8% in premarket... Read more
7 related stories
9d
FOX Business
Merck Revenue and Profit FallsMerck posted declines in sales and profit as the pharmaceutical giant gave reve
Merck Revenue and Profit Falls
FOX Business / Posted 9 days ago
Merck posted declines in sales and profit as the pharmaceutical giant gave revenue projections below analyst forecasts and earnings expectations on the lower end of them. Shares, which have fallen 6% in the last three months, fell 2.8% in premarket... Read more
9d
Your Hometown Lima Stations
Merck beats 4Q profit forecast, misses Street view on salesMerck & Co. posted an 87 percent drop in fourth-quarter profit compared with la
Merck beats 4Q profit forecast, misses Street view on sales
Your Hometown Lima Stations / Posted 9 days ago
Merck & Co. posted an 87 percent drop in fourth-quarter profit compared with last year when the drugmaker had a huge gain from the sale of consumer health business. The strong dollar and increasing competition for some of its older medicines cut... Read more
7 related stories
9d
The Sacramento Bee
Doctors, activists push for new PrEP treatment to prevent HIV spreadUntil recently, George Raya couldn’t talk about the AIDS epidemic that killed h
Doctors, activists push for new PrEP treatment to prevent HIV spread
The Sacramento Bee / Posted 9 days ago
Until recently, George Raya couldn’t talk about the AIDS epidemic that killed hundreds of thousands of gay men in the 1980s and ’90s. He had lost half his address book to the virus during that time in San Francisco, he said, and thinking about it... Read more
13 related stories
10d
Business Wire
Gilead Sciences annuncia la dichiarazione del dividendo in contanti per il primo trimestre e degli aumenti per quanto concerne i programmi per la crescita del rendimento a favore degli azionistiFOSTER CITY, California--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD)
Gilead Sciences annuncia la dichiarazione del dividendo in contanti per il primo trimestre e degli aumenti per quanto concerne i programmi per la crescita del rendimento a favore degli azionisti
Business Wire / Posted 10 days ago
FOSTER CITY, California--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) ha annunciato oggi che il Consiglio di amministrazione della società ha dichiarato un dividendo in contanti di $0,43 per azione ordinaria per il primo trimestre del 2016.... Read more
71 related stories
10d
Business Wire
Gilead Sciences maakt declaratie bekend van dividend in contanten voor het eerste kwartaal en verhogingen in aandeelhoudersrendementprogramma'sFOSTER CITY, Californië--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD)
Gilead Sciences maakt declaratie bekend van dividend in contanten voor het eerste kwartaal en verhogingen in aandeelhoudersrendementprogramma's
Business Wire / Posted 10 days ago
FOSTER CITY, Californië--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) heeft vandaag bekendgemaakt dat de raad van bestuur van het bedrijf een dividend in contanten van $ 0,43 per gewoon aandeel heeft gedeclareerd voor het eerste kwartaal van... Read more
26 related stories
10d
Morningstar
Dow Logs Nearly 300-point Loss As Oil Sinks Below $30Wall Street stocks ended sharply lower Tuesday as investors unloaded energy and
Dow Logs Nearly 300-point Loss As Oil Sinks Below $30
Morningstar / Posted 10 days ago
Wall Street stocks ended sharply lower Tuesday as investors unloaded energy and financial stocks amid a selloff in crude-oil futures, which settled below $30 a barrel. The downdraft in energy shares and banks offset strong gains in Google parent... Read more
3 related stories
10d
KOB 4 Albuquerque
Gilead Sciences beats Street 4th-quarter forecastsGilead Sciences Inc. posted a 34 percent increase in fourth-quarter profit, tro
Gilead Sciences beats Street 4th-quarter forecasts
KOB 4 Albuquerque / Posted 10 days ago
Gilead Sciences Inc. posted a 34 percent increase in fourth-quarter profit, trouncing Wall Street expectations, as sales of its blockbuster hepatitis C drugs soared in Japan and offset lower sales in the U.S. The maker of Harvoni, the first... Read more
8 related stories
10d
The Tampa Tribune
Gilead Sciences beats Street 4th-quarter forecastsGilead Sciences Inc. posted a 34 percent increase in fourth-quarter profit, tro
Gilead Sciences beats Street 4th-quarter forecasts
The Tampa Tribune / Posted 10 days ago
Gilead Sciences Inc. posted a 34 percent increase in fourth-quarter profit, trouncing Wall Street expectations, as sales of its blockbuster hepatitis C drugs soared in Japan and offset lower sales in the U.S. The maker of Harvoni, the first... Read more
8 related stories
10d
Market Watch
Gilead hepatitis C drugs beat sales viewsGilead Sciences Inc. said its two hepatitis drugs, Sovaldi and Harvoni, generat
Gilead hepatitis C drugs beat sales views
Market Watch / Posted 10 days ago
Gilead Sciences Inc. said its two hepatitis drugs, Sovaldi and Harvoni, generated combined sales of $4.89 billion world-wide during the fourth quarter, topping analysts' expectations for global sales of $4.45 billion. The Foster City, Calif.,... Read more
10d
FOX Business
Gilead Sciences Shares Rise On Earnings, Revenue BeatGilead Sciences Inc. shares rose in the extended session Tuesday after the biot
Gilead Sciences Shares Rise On Earnings, Revenue Beat
FOX Business / Posted 10 days ago
Gilead Sciences Inc. shares rose in the extended session Tuesday after the biotech topped Wall Street estimates on earnings and revenue for the quarter. Gilead shares advanced 2.2% to $84.48. The company reported adjusted fourth-quarter earnings of... Read more
8 related stories
10d
FOX Business
Gilead Sciences Shares Rise On Earnings, Revenue BeatGilead Sciences Inc. shares rose in the extended session Tuesday after the biot
Gilead Sciences Shares Rise On Earnings, Revenue Beat
FOX Business / Posted 10 days ago
Gilead Sciences Inc. shares rose in the extended session Tuesday after the biotech topped Wall Street estimates on earnings and revenue for the quarter. Gilead shares advanced 2.2% to $84.48. The company reported adjusted fourth-quarter earnings of... Read more
17 related stories
10d
Market Watch
Gilead Sciences shares rise on earnings, revenue beatGilead Sciences Inc. GILD, -1.60% shares rose in the extended session Tuesday a
Gilead Sciences shares rise on earnings, revenue beat
Market Watch / Posted 10 days ago
Gilead Sciences Inc. GILD, -1.60% shares rose in the extended session Tuesday after the biotech topped Wall Street estimates on earnings and revenue for the quarter. Gilead shares advanced 2.2% to $84.48. The company reported adjusted fourth-quarter... Read more
8 related stories
10d
Business Wire
Gilead maakt bevordering bekend van Katie Watson tot Executive Vice President, Human ResourcesFOSTER CITY, Californië--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD)
Gilead maakt bevordering bekend van Katie Watson tot Executive Vice President, Human Resources
Business Wire / Posted 10 days ago
FOSTER CITY, Californië--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) maakte vandaag de bevordering bekend van Katie Watson tot Executive Vice President, Human Resources. Mevr. Watson is sinds februari 2003 werkzaam voor Gilead en heeft... Read more
26 related stories
11d
Business Wire
Gilead gibt Beförderung von Katie Watson zum Executive Vice President Human Resources bekanntFOSTER CITY, Kalifornien--(BUSINESS WIRE)--Das Unternehmen Gilead Sciences, Inc
Gilead gibt Beförderung von Katie Watson zum Executive Vice President Human Resources bekannt
Business Wire / Posted 11 days ago
FOSTER CITY, Kalifornien--(BUSINESS WIRE)--Das Unternehmen Gilead Sciences, Inc. (Nasdaq: GILD) gab heute die Beförderung von Katie Watson zum Executive Vice President für das Ressort Human Resources bekannt. Frau Watson ist seit Februar 2003 bei... Read more
2966 related stories
11d
Business Wire
European Medicines Agency valideert Gilead's type-II-variatietoepassing voor Truvada® voor het verlagen van het risico op seksueel opgelopen hivFOSTER CITY, Californië--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) h
European Medicines Agency valideert Gilead's type-II-variatietoepassing voor Truvada® voor het verlagen van het risico op seksueel opgelopen hiv
Business Wire / Posted 11 days ago
FOSTER CITY, Californië--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) heeft vandaag bekend gemaakt dat de type-II-variatie van het bedrijf voor Truvada® (emtricitabine 200 mg/tenofovirdisoproxilfumaraat 300 mg) eenmaal daags in combinatie met... Read more
26 related stories
11d
Business Wire
Gilead annuncia la promozione di Katie Watson a vicepresidente esecutivo, Risorse UmaneFOSTER CITY, California--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD)
Gilead annuncia la promozione di Katie Watson a vicepresidente esecutivo, Risorse Umane
Business Wire / Posted 11 days ago
FOSTER CITY, California--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) ha annunciato quest'oggi la promozione di Katie Watson a vicepresidente esecutivo, Risorse Umane. La Signora Watson si è unita a Gilead nel febbraio 2003 e da allora ha... Read more
71 related stories
11d
Business Wire
Gilead annonce la promotion de Katie Watson au poste de vice-présidente exécutive des ressources humainesFOSTER CITY, Californie--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq : GILD)
Gilead annonce la promotion de Katie Watson au poste de vice-présidente exécutive des ressources humaines
Business Wire / Posted 11 days ago
FOSTER CITY, Californie--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq : GILD) a annoncé aujourd’hui la promotion de Katie Watson au poste de vice-présidente exécutive des ressources humaines. Katie Watson a rejoint Gilead en février 2003, et... Read more
502 related stories
11d
Investopedia
The Biggest Risks of Investing in Celgene Stock (CELG)Celgene Corporation (NASDAQ: CELG) is a biopharmaceutical company that research
The Biggest Risks of Investing in Celgene Stock (CELG)
Investopedia / Posted 11 days ago
Celgene Corporation (NASDAQ: CELG) is a biopharmaceutical company that researches and develops drugs for treating inflammatory diseases and various types of cancer. Celgene's core drugs are Revlimid, which makes up 66% of sales, Abraxane and... Read more
11d
Business Wire
L'agenzia europea preposta al controllo dei farmaci convalida la domanda di variazione di tipo II depositata da Gilead per Truvada® per la riduzione del rischio di contrazione dell’infezione da HIV per via sessualeFOSTER CITY, California--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) h
L'agenzia europea preposta al controllo dei farmaci convalida la domanda di variazione di tipo II depositata da Gilead per Truvada® per la riduzione del rischio di contrazione dell’infezione da HIV per via sessuale
Business Wire / Posted 11 days ago
FOSTER CITY, California--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) ha annunciato oggi che la domanda di variazione di tipo II depositata dalla società per il farmaco a somministrazione monogiornaliera Truvada® (emtricitabina 200... Read more
71 related stories
14d
ABC News
Xerox, Microsoft and Honeywell Rise While Amazon SkidsXerox Corp., up 52 cents to $9.75 The printer and copier maker will split in t
Xerox, Microsoft and Honeywell Rise While Amazon Skids
ABC News / Posted 14 days ago
Xerox Corp., up 52 cents to $9.75 The printer and copier maker will split in two, spinning off its services business, following a push from activist investor Carl Icahn. The industrial conglomerate gained ground after its fourth-quarter earnings... Read more
14d
The Globe and Mail
Calendar: What investors need to know for the week aheadA daily rundown of the economic reports and corporate earnings that will be gra
Calendar: What investors need to know for the week ahead
The Globe and Mail / Posted 14 days ago
A daily rundown of the economic reports and corporate earnings that will be grabbing the market's attention in the week ahead.Monday February 1 Japan, China and Euro area manufacturing purchasing managers' index (PMI) (8:30 a.m. ET) U.S. personal... Read more
14d
FOX Business
Gilead Says Milligan Will Replace Current CEO John Martin, Who Will Become Exec ChairmanGilead Sciences Inc.'s said Friday in pre-market trade that chairman and 20-yea
Gilead Says Milligan Will Replace Current CEO John Martin, Who Will Become Exec Chairman
FOX Business / Posted 14 days ago
Gilead Sciences Inc.'s said Friday in pre-market trade that chairman and 20-year chief executive officer John Martin will become the company's executive chairman, effective March 10. He will be replaced by president and chief operating officer John... Read more
2 related stories
14d
FOX Business
Gilead Says Milligan Will Replace Current CEO John Martin, Who Will Become Exec ChairmanGilead Sciences Inc.'s said Friday in pre-market trade that chairman and 20-yea
Gilead Says Milligan Will Replace Current CEO John Martin, Who Will Become Exec Chairman
FOX Business / Posted 14 days ago
Gilead Sciences Inc.'s said Friday in pre-market trade that chairman and 20-year chief executive officer John Martin will become the company's executive chairman, effective March 10. He will be replaced by president and chief operating officer John... Read more
2 related stories
14d
National Post
Story | Business Wire News Releases | News | Financial PostFOSTER CITY, Californie--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq : GILD)
Story | Business Wire News Releases | News | Financial Post
National Post / Posted 14 days ago
FOSTER CITY, Californie--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq : GILD) a annoncé aujourd’hui que, le 10 mars 2016, le président-directeur-général actuel, John C. Martin, PhD, va assumer le rôle de président exécutif de la société. John F.... Read more
502 related stories
14d
Business Wire
John C. Martin, PhD, di Gilead assumerà la carica di Presidente esecutivo del Consiglio di Amministrazione; John F. Milligan, PhD, sarà nominato Amministratore delegato (AD) e DirettoreFOSTER CITY, California--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) h
John C. Martin, PhD, di Gilead assumerà la carica di Presidente esecutivo del Consiglio di Amministrazione; John F. Milligan, PhD, sarà nominato Amministratore delegato (AD) e Direttore
Business Wire / Posted 14 days ago
FOSTER CITY, California--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) ha annunciato in data odierna che, con decorrenza a partire dal 10 marzo 2016, l’attuale Presidente e AD John C. Martin, PhD, assumerà la carica di Presidente esecutivo... Read more
21 related stories
14d
Business Wire
Gilead’s John C. Martin, PhD wordt uitvoerend voorzitter van de raad van bestuur; John F. Milligan, PhD wordt aangesteld als president-directeurFOSTER CITY, Californië--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) h
Gilead’s John C. Martin, PhD wordt uitvoerend voorzitter van de raad van bestuur; John F. Milligan, PhD wordt aangesteld als president-directeur
Business Wire / Posted 14 days ago
FOSTER CITY, Californië--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) heeft vandaag bekend gemaakt dat, met ingang van 10 maart 2016, de huidige directeur en CEO John C. Martin, PhD de rol van uitvoerend voorzitter van de raad van bestuur van... Read more
18 related stories
14d
Business Wire
John C. Martin, PhD de Gilead asumirá el cargo de Presidente ejecutivo del Consejo de Administración; John F. Milligan, PhD, será nombrado CEO y miembro del ConsejoFOSTER CITY, California--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) h
John C. Martin, PhD de Gilead asumirá el cargo de Presidente ejecutivo del Consejo de Administración; John F. Milligan, PhD, será nombrado CEO y miembro del Consejo
Business Wire / Posted 14 days ago
FOSTER CITY, California--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) ha anunciado que, con efecto a partir del 10 de marzo, 2016, el actual Presidente del Consejo de Administración y CEO, John C. Martin, PhD, asumirá el puesto de Presidente... Read more
3682 related stories
14d
Business Wire
Gileads Dr. John C. Martin wird Executive Chairman of the Board – Dr. John F. Milligan wird zum Chief Executive Officer und Direktor berufenFOSTER CITY, Kalifornien (USA)--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:
Gileads Dr. John C. Martin wird Executive Chairman of the Board – Dr. John F. Milligan wird zum Chief Executive Officer und Direktor berufen
Business Wire / Posted 14 days ago
FOSTER CITY, Kalifornien (USA)--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) hat heute bekannt gegeben, dass mit Wirkung vom 10. März 2016 der gegenwärtige Chairman und CEO Dr. John C. Martin die Funktion des Executive Chairman im Unternehmen... Read more
2966 related stories
14d
Business Wire
John C. Martin, PhD, de Gilead va assumer le rôle de président exécutif du conseil d’administration ; John F. Milligan, PhD, sera nommé président-directeur général et administrateurFOSTER CITY, Californie--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq : GILD)
John C. Martin, PhD, de Gilead va assumer le rôle de président exécutif du conseil d’administration ; John F. Milligan, PhD, sera nommé président-directeur général et administrateur
Business Wire / Posted 14 days ago
FOSTER CITY, Californie--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq : GILD) a annoncé aujourd’hui que, le 10 mars 2016, le président-directeur-général actuel, John C. Martin, PhD, va assumer le rôle de président exécutif de la société. John F.... Read more
502 related stories
14d
National Post
Story | Business Wire News Releases | News | Financial PostFOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today
Story | Business Wire News Releases | News | Financial Post
National Post / Posted 14 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that, effective March 10, 2016, current Chairman and CEO John C. Martin, PhD will assume the role of Executive Chairman of the company. John F. Milligan, PhD,... Read more
2 related stories
15d
Channel NewsAsia
FDA approves Merck's new hepatitis C pillREUTERS: U.S. regulators on Thursday approved a new once-daily pill for the liv
FDA approves Merck's new hepatitis C pill
Channel NewsAsia / Posted 15 days ago
REUTERS: U.S. regulators on Thursday approved a new once-daily pill for the liver-destroying hepatitis C virus made by Merck & Co Inc, which said it will sell the drug at a lower list price than its competitors. The list price for Zepatier will be... Read more
16 related stories
15d
Hawaii News Now
FDA OKs Merck hepatitis C drug, adding to patient choicesTRENTON, N.J. (AP) - Patients with hepatitis C have yet another advanced treatm
FDA OKs Merck hepatitis C drug, adding to patient choices
Hawaii News Now / Posted 15 days ago
TRENTON, N.J. (AP) - Patients with hepatitis C have yet another advanced treatment option, as the Food and Drug Administration on Thursday approved a new once-a-day pill developed by drugmaker Merck. The FDA said Merck can begin marketing Zepatier... Read more
16 related stories
15d
Market Watch
FDA OK’s Merck’s new hepatitis C drugThe U.S. Food and Drug Administration approved Merck & Co.’s new treatment for
FDA OK’s Merck’s new hepatitis C drug
Market Watch / Posted 15 days ago
The U.S. Food and Drug Administration approved Merck & Co.’s new treatment for hepatitis C, the latest entrant in a booming market for drugs for the viral infection — a market now dominated by Gilead Sciences Inc. Merck’s MRK, -2.32% treatment,... Read more
16 related stories
15d
ABC News
FDA OKs Merck Hepatitis C Drug, Adding to Patient ChoicesPatients with hepatitis C have yet another advanced treatment option, as the Fo
FDA OKs Merck Hepatitis C Drug, Adding to Patient Choices
ABC News / Posted 15 days ago
Patients with hepatitis C have yet another advanced treatment option, as the Food and Drug Administration on Thursday approved a new once-a-day pill developed by drugmaker Merck. The FDA said Merck can begin marketing Zepatier for patients with two... Read more
16 related stories
15d
Your Hometown Lima Stations
FDA OKs Merck hepatitis C drug, adding to patient choicesTRENTON, N.J. (AP) - Patients with hepatitis C have yet another advanced treatm
FDA OKs Merck hepatitis C drug, adding to patient choices
Your Hometown Lima Stations / Posted 15 days ago
TRENTON, N.J. (AP) - Patients with hepatitis C have yet another advanced treatment option, as the Food and Drug Administration on Thursday approved a new once-a-day pill developed by drugmaker Merck. The FDA said Merck can begin marketing Zepatier... Read more
16 related stories
15d
KTEN North Texas & Southeastern Oklahoma
FDA OKs Merck hepatitis C drug, adding to patient choicesTRENTON, N.J. (AP) - Patients with hepatitis C have yet another advanced treatm
FDA OKs Merck hepatitis C drug, adding to patient choices
KTEN North Texas & Southeastern Oklahoma / Posted 15 days ago
TRENTON, N.J. (AP) - Patients with hepatitis C have yet another advanced treatment option, as the Food on Drug Administration on Thursday approved a new once-a-day pill developed by drugmaker Merck. The FDA said Merck can begin marketing Zepatier... Read more
16 related stories
15d
Your Hometown Lima Stations
Massachusetts is investigating high cost of hepatitis C drugBOSTON (AP) - The Massachusetts attorney general's office said Wednesday that i
Massachusetts is investigating high cost of hepatitis C drug
Your Hometown Lima Stations / Posted 15 days ago
BOSTON (AP) - The Massachusetts attorney general's office said Wednesday that it is investigating whether the makers of a breakthrough treatment for hepatitis C are violating state law by pricing the drugs too high. Attorney General Maura Healey on... Read more
9 related stories
15d
The Nashua Telegraph
Mass. investigating high cost of hepatitis C drugBOSTON - The Massachusetts attorney general's office said Wednesday that it is
Mass. investigating high cost of hepatitis C drug
The Nashua Telegraph / Posted 15 days ago
BOSTON - The Massachusetts attorney general's office said Wednesday that it is investigating whether the makers of a breakthrough treatment for hepatitis C are violating state law by pricing the drugs too high. Attorney General Maura Healey on... Read more
9 related stories
16d
Air Force Times
Hepatitis C drug maker is price-gouging, GOP lawmaker saysThe chairman of the House Veterans' Affairs Committee has accused the makers of
Hepatitis C drug maker is price-gouging, GOP lawmaker says
Air Force Times / Posted 16 days ago
The chairman of the House Veterans' Affairs Committee has accused the makers of hepatitis C drug sofosbuvir of opportunism and price-gouging for charging the U.S. government up to $68,000 for a treatment regimen that costs about $1,400 to... Read more
16d
The Columbian
Massachusetts is investigating high cost of hepatitis C drugBOSTON — The Massachusetts attorney general’s office is investigating whether t
Massachusetts is investigating high cost of hepatitis C drug
The Columbian / Posted 16 days ago
BOSTON — The Massachusetts attorney general’s office is investigating whether the makers of a breakthrough treatment for hepatitis C are violating state law by pricing the drug too high. Attorney General Maura Healey on Wednesday released a letter... Read more
9 related stories
16d
FOX News
Massachusetts is investigating high cost of hepatitis C drugThe Massachusetts attorney general's office is investigating whether the makers
Massachusetts is investigating high cost of hepatitis C drug
FOX News / Posted 16 days ago
The Massachusetts attorney general's office is investigating whether the makers of a breakthrough treatment for hepatitis C are violating state law by pricing the drug too high. Attorney General Maura Healey on Wednesday released a letter sent to... Read more
9 related stories
16d
The Tampa Tribune
Massachusetts is investigating high cost of hepatitis C drugBOSTON (AP) � The Massachusetts attorney general's office is investigating whet
Massachusetts is investigating high cost of hepatitis C drug
The Tampa Tribune / Posted 16 days ago
BOSTON (AP) � The Massachusetts attorney general's office is investigating whether the makers of a breakthrough treatment for hepatitis C are violating state law by pricing the drug too high. Attorney General Maura Healey on Wednesday released a... Read more
9 related stories
16d
Boston Globe
Massachusetts is investigating high cost of hepatitis C drugBOSTON (AP) — The Massachusetts attorney general’s office is investigating whet
Massachusetts is investigating high cost of hepatitis C drug
Boston Globe / Posted 16 days ago
BOSTON (AP) — The Massachusetts attorney general’s office is investigating whether the makers of a breakthrough treatment for hepatitis C are violating state law by pricing the drug too high. Attorney General Maura Healey on Wednesday released a... Read more
9 related stories
16d
ABC 6 Providence
Massachusetts is investigating high cost of hepatitis C drugBOSTON (AP) - The Massachusetts attorney general's office is investigating whet
Massachusetts is investigating high cost of hepatitis C drug
ABC 6 Providence / Posted 16 days ago
BOSTON (AP) - The Massachusetts attorney general's office is investigating whether the makers of a breakthrough treatment for hepatitis C are violating state law by pricing the drug too high. Attorney General Maura Healey on Wednesday released a... Read more
9 related stories
More

People in this news